Exact Mass: 463.1716
Exact Mass Matches: 463.1716
Found 244 metabolites which its exact mass value is equals to given mass value 463.1716
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Pivampicillin
Pivampicillin is only found in individuals that have used or taken this drug. It is an analog of ampicillin.Ampicillin (the active metabolite of pivampicillin) has a bactericidal action resulting from inhibition of cell wall mucopeptide biosynthesis. J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01C - Beta-lactam antibacterials, penicillins > J01CA - Penicillins with extended spectrum D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D010406 - Penicillins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic Same as: D08396
N-Carbobenzoxyglycyl-prolyl-4-methylcoumarinyl amide
pivampicillin
J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01C - Beta-lactam antibacterials, penicillins > J01CA - Penicillins with extended spectrum D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D010406 - Penicillins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic Same as: D08396
8-2-Amino-3-methylimidazo[4,5-f]quinoline-deoxyguanosine
Ala Asp Met Gln
Ala Asp Gln Met
Ala Glu Met Asn
Ala Glu Asn Met
Ala Met Asp Gln
Ala Met Glu Asn
Ala Met Asn Glu
Ala Met Gln Asp
Ala Asn Glu Met
Ala Asn Met Glu
Ala Gln Asp Met
Ala Gln Met Asp
Cys Asp Ile Asn
Cys Asp Leu Asn
Cys Asp Asn Ile
Cys Asp Asn Leu
Cys Asp Gln Val
Cys Asp Val Gln
Cys Glu Asn Val
Cys Glu Val Asn
Cys Ile Asp Asn
Cys Ile Asn Asp
Cys Leu Asp Asn
Cys Leu Asn Asp
Cys Asn Asp Ile
Cys Asn Asp Leu
Cys Asn Glu Val
Cys Asn Ile Asp
Cys Asn Leu Asp
Cys Asn Val Glu
Cys Gln Asp Val
Cys Gln Val Asp
Cys Val Asp Gln
Cys Val Glu Asn
Cys Val Asn Glu
Cys Val Gln Asp
Asp Ala Met Gln
Asp Ala Gln Met
Asp Cys Ile Asn
Asp Cys Leu Asn
Asp Cys Asn Ile
Asp Cys Asn Leu
Asp Cys Gln Val
Asp Cys Val Gln
Asp Gly Ser Trp
Asp Gly Trp Ser
Asp Ile Cys Asn
Asp Ile Asn Cys
Asp Leu Cys Asn
Asp Leu Asn Cys
Asp Met Ala Gln
Asp Met Gln Ala
Asp Asn Cys Ile
Asp Asn Cys Leu
Asp Asn Ile Cys
Asp Asn Leu Cys
Asp Gln Ala Met
Asp Gln Cys Val
Asp Gln Met Ala
Asp Gln Val Cys
Asp Ser Gly Trp
Asp Ser Trp Gly
Asp Val Cys Gln
Asp Val Gln Cys
Asp Trp Gly Ser
Asp Trp Ser Gly
Glu Ala Met Asn
Glu Ala Asn Met
Glu Cys Asn Val
Glu Cys Val Asn
Glu Gly Met Gln
Glu Gly Gln Met
Glu Met Ala Asn
Glu Met Gly Gln
Glu Met Asn Ala
Glu Met Gln Gly
Glu Asn Ala Met
Glu Asn Cys Val
Glu Asn Met Ala
Glu Asn Val Cys
Glu Gln Gly Met
Glu Gln Met Gly
Glu Val Cys Asn
Glu Val Asn Cys
Gly Asp Ser Trp
Gly Asp Trp Ser
Gly Glu Met Gln
Gly Glu Gln Met
Gly Met Glu Gln
Gly Met Gln Glu
Gly Gln Glu Met
Gly Gln Met Glu
Gly Ser Asp Trp
Gly Ser Trp Asp
Gly Trp Asp Ser
Gly Trp Ser Asp
Ile Cys Asp Asn
Ile Cys Asn Asp
Ile Asp Cys Asn
Ile Asp Asn Cys
Ile Asn Cys Asp
Ile Asn Asp Cys
Leu Cys Asp Asn
Leu Cys Asn Asp
Leu Asp Cys Asn
Leu Asp Asn Cys
Leu Asn Cys Asp
Leu Asn Asp Cys
Met Ala Asp Gln
Met Ala Glu Asn
Met Ala Asn Glu
Met Ala Gln Asp
Met Asp Ala Gln
Met Asp Gln Ala
Met Glu Ala Asn
Met Glu Gly Gln
Met Glu Asn Ala
Met Glu Gln Gly
Met Gly Glu Gln
Met Gly Gln Glu
Met Asn Ala Glu
Met Asn Glu Ala
Met Gln Ala Asp
Met Gln Asp Ala
Met Gln Glu Gly
Met Gln Gly Glu
Asn Ala Glu Met
Asn Ala Met Glu
Asn Cys Asp Ile
Asn Cys Asp Leu
Asn Cys Glu Val
Asn Cys Ile Asp
Asn Cys Leu Asp
Asn Cys Val Glu
Asn Asp Cys Ile
Asn Asp Cys Leu
Asn Asp Ile Cys
Asn Asp Leu Cys
Asn Glu Ala Met
Asn Glu Cys Val
Asn Glu Met Ala
Asn Glu Val Cys
Asn Ile Cys Asp
Asn Ile Asp Cys
Asn Leu Cys Asp
Asn Leu Asp Cys
Asn Met Ala Glu
Asn Met Glu Ala
Asn Val Cys Glu
Asn Val Glu Cys
Gln Ala Asp Met
Gln Ala Met Asp
Gln Cys Asp Val
Gln Cys Val Asp
Gln Asp Ala Met
Gln Asp Cys Val
Gln Asp Met Ala
Gln Asp Val Cys
Gln Glu Gly Met
Gln Glu Met Gly
Gln Gly Glu Met
Gln Gly Met Glu
Gln Met Ala Asp
Gln Met Asp Ala
Gln Met Glu Gly
Gln Met Gly Glu
Gln Val Cys Asp
Gln Val Asp Cys
Ser Asp Gly Trp
Ser Asp Trp Gly
Ser Gly Asp Trp
Ser Gly Trp Asp
Ser Trp Asp Gly
Ser Trp Gly Asp
Val Cys Asp Gln
Val Cys Glu Asn
Val Cys Asn Glu
Val Cys Gln Asp
Val Asp Cys Gln
Val Asp Gln Cys
Val Glu Cys Asn
Val Glu Asn Cys
Val Asn Cys Glu
Val Asn Glu Cys
Val Gln Cys Asp
Val Gln Asp Cys
Trp Asp Gly Ser
Trp Asp Ser Gly
Trp Gly Asp Ser
Trp Gly Ser Asp
Trp Ser Asp Gly
Trp Ser Gly Asp
3-[[9,10-dihydro-4-(methylamino)-9,10-dioxo-1-anthryl]aminopropyl]trimethylammonium methyl sulphate
2-ethoxyethyl [2-[(2-chloro-4-nitrophenyl)azo]-5-(diethylamino)phenyl]carbamate
N-(6-Methoxy-3-pyridinyl)-1,2-dimethyl-N-{[5-(2-methylphenyl)-2-p yridinyl]methyl}-1H-imidazole-4-sulfonamide
Berzosertib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
(E)-3-[9-methyl-2-(4-methylpiperazin-1-yl)-4-oxopyrido[1,2-a]pyrimidin-3-yl]-2-(4-methylphenyl)sulfonylprop-2-enenitrile
N-(1,3-benzodioxol-5-ylmethyl)-N-[2-(cyclohexylamino)-2-oxo-1-pyridin-4-ylethyl]-2,2,2-trifluoroacetamide
N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-4-methoxy-N-methylbenzenesulfonamide
1-[(2S,3S,6R)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2-methoxyphenyl)urea
1-[(2R,3R,6R)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2-methoxyphenyl)urea
1-[(2S,3R,6R)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)oxan-3-yl]-3-(2-methoxyphenyl)urea
1-[(2S,3S,6S)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2-methoxyphenyl)urea
N-[2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[(4-methoxyphenyl)sulfonylamino]-2-oxanyl]ethyl]-2-(2-pyridinyl)acetamide
N-[2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[(4-methoxyphenyl)sulfonylamino]-2-oxanyl]ethyl]-2-(2-pyridinyl)acetamide
N-[2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[(4-methoxyphenyl)sulfonylamino]-2-oxanyl]ethyl]-2-(2-pyridinyl)acetamide
(6R,7S,8S)-N-(4-fluorophenyl)-7-[4-(3-fluorophenyl)phenyl]-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6S,7S,8R)-N-(4-fluorophenyl)-7-[4-(3-fluorophenyl)phenyl]-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6R,7S,8R)-N-(4-fluorophenyl)-7-[4-(3-fluorophenyl)phenyl]-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
1-[(2S,3R,6S)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2-methoxyphenyl)urea
1-[(2R,3S,6R)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2-methoxyphenyl)urea
1-[(2R,3S,6S)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2-methoxyphenyl)urea
1-[(2R,3R,6S)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2-methoxyphenyl)urea
N-[2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[(4-methoxyphenyl)sulfonylamino]-2-oxanyl]ethyl]-2-(2-pyridinyl)acetamide
N-[2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[(4-methoxyphenyl)sulfonylamino]-2-oxanyl]ethyl]-2-(2-pyridinyl)acetamide
N-[2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[(4-methoxyphenyl)sulfonylamino]-2-oxanyl]ethyl]-2-(2-pyridinyl)acetamide
N-[2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[(4-methoxyphenyl)sulfonylamino]-2-oxanyl]ethyl]-2-(2-pyridinyl)acetamide
N-[2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[(4-methoxyphenyl)sulfonylamino]-2-oxanyl]ethyl]-2-(2-pyridinyl)acetamide
(6R,7R,8S)-N-(4-fluorophenyl)-7-[4-(3-fluorophenyl)phenyl]-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6R,7R,8R)-N-(4-fluorophenyl)-7-[4-(3-fluorophenyl)phenyl]-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6S,7R,8R)-N-(4-fluorophenyl)-7-[4-(3-fluorophenyl)phenyl]-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6S,7R,8S)-N-(4-fluorophenyl)-7-[4-(3-fluorophenyl)phenyl]-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6S,7S,8S)-N-(4-fluorophenyl)-7-[4-(3-fluorophenyl)phenyl]-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
2,2-dimethylpropanoyloxymethyl (2S,5S,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
MGL-IN-1
MGL-IN-1 is a potent and selective irreversible MGL (β-lactam-based monoacylglycerol lipase) inhibitor. MGL-IN-1 alleviates symptoms in a MS model in vivo and exhibits analgesic effects in an acute inflammatory pain model in vivo. MGL-IN-1 displays high membrane permeability and brain penetrant[1].